{
    "clinical_study": {
        "@rank": "75445", 
        "arm_group": {
            "arm_group_label": "cohort"
        }, 
        "brief_summary": {
            "textblock": "This observastonal multicenter study will evaluate the differences of progression-free\n      survival in defined subgroups of patients with metastatic colorectal cancer receiving\n      Avastin (bevacizumab). Further, safety and efficacy in daily routine will be assessed. Data\n      will be collected for up to 5 years."
        }, 
        "brief_title": "An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (Koralle)", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >= 18 years\n\n          -  Patients with metastatic colorectal cancer where investigators have decided to give a\n             first-line, fluoro-pyrimidine-based combination therapy with Avastin\u00ae according to\n             Summary of Product Characteristics (SmPC)\n\n          -  Written and signed informed consent prior to onset of documentation\n\n        Exclusion Criteria:\n\n          -  Contraindications for Avastin\u00ae according to Summary of Products Characteristics\n             (SmPC)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with Metastatic colorectal cancer"
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775644", 
            "org_study_id": "ML28120"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Freiburg", 
                    "country": "Germany", 
                    "zip": "79106"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non-interventional Study of Avastin\u00ae First-line in Metastatic Colorectal Cancer (Koralle)", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28120 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices(Bfarm)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Differences in progression-free survival of patient subgroups", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775644"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical/demographic patient characteristics at initiation of treatment", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Progression-free survival in daily routine", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Overall response in daily routine", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Response rate in daily routine", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Treatment schemes in daily routine", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Safety: incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Reason for treatment modifications/discontinuation", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}